Certara Products Archives

Publication

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Bioavailability of orally administered drugs can be influenced by a number of factors including release…

CertaraNovember 1, 2015

Announcement

Introducing OpenCDISC Enterprise 3.0

Pinnacle 21 is proud to announce the launch of OpenCDISC Enterprise 3.0, which will be…

CertaraOctober 27, 2015

Announcement

Max Kanevsky named to the PharmaVOICE 100 List of the Most Inspiring People

Certara’s Pinnacle 21 is honored to announce that Max Kanevsky, has been named to the…

CertaraAugust 5, 2015

Blog

Common Misconceptions About Computer System Validation

Drug development professionals frequently use computer systems to help them understand the pharmacokinetics (PK) and…

CertaraJanuary 28, 2015

Blog

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

As a scientist at Certara and proud Dad to my three kids, pediatric drug development…

CertaraJanuary 15, 2015

Publication

Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics

In drug development, considerable efforts are made to extrapolate from in vitro and preclinical findings…

CertaraOctober 1, 2014

Blog

FDA DataFit: an introduction

Explore FDA DataFit, a project ensuring high-quality, compliant data to streamline drug reviews, reduce delays,…

CertaraAugust 19, 2014

Blog

FDA JumpStart: an introduction

Discover FDA JumpStart, a ground-breaking service accelerating drug reviews by enhancing data quality, identifying risks,…

CertaraJuly 16, 2014

Publication

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

Typically, pharmacokinetic-pharmacodynamic (PK/PD) models use plasma concentration as the input that drives the PD model. However, interindividual variability in…

CertaraJuly 9, 2014

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin…

CertaraSeptember 1, 2013

Certara Products

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Introducing OpenCDISC Enterprise 3.0

Max Kanevsky named to the PharmaVOICE 100 List of the Most Inspiring People

Common Misconceptions About Computer System Validation

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics

FDA DataFit: an introduction

FDA JumpStart: an introduction

Application of a Physiologically-based Pharmacokinetic Model to Predict OATP1B1-related Variability in Pharmacodynamics of Rosuvastatin

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

Newsletter sign up

Quick links

Solutions

Contact